FZD6 and cancer: The antibody binds to Fzds 1, 2, 5, 7 and 8, and has been shown to reduce activation of canonical wnt signalling in preclinical cancer models.74 One could envisage that a naked or toxin conjugated monoclonal antibody targeting Fzd6 could be developed to treat cancers bearing high Fzd6 expression levels.